The introduction of rifampicin (rifampin) into tuberculosis (TB) treatment five decades ago
was critical for shortening the treatment duration for patients with pulmonary TB to 6 months …

High doses of rifampin may help patients with tuberculous meningitis (TBM) to survive.
Pharmacokinetic pharmacodynamic evaluations suggested that rifampin doses higher than …

The 4-drug regimen of rifampin, isoniazid, pyrazinamide, and ethambutol is an inexpensive,
reliable option for treating patients with drug-susceptible tuberculosis (TB). Its efficacy could …

Background Patients affected by poverty-related infectious diseases (PRDs) are
disproportionally affected by malnutrition. To optimize treatment of patients affected by …

Tuberculosis (TB) and hepatitis C virus (HCV) infections are both major public health
problems. Despite high rates of coinfection, there is scarce literature addressing the …

The oral multikinase inhibitor sorafenib undergoes extensive UGT1A9‐mediated formation
of sorafenib‐β‐D‐glucuronide (SG). Using transporter‐deficient mouse models, it was …

Rifampicin is the most important antibiotic in use for the treatment of tuberculosis (TB).
Preclinical and clinical data suggest that higher doses of rifampicin, resulting in …

Objectives Malnutrition is associated with a twofold higher risk of dying in patients with
tuberculosis (TB) and considered an important potentially reversible risk factor for failure of …

Objectives Mycobacterium avium complex (MAC) bacteria can cause chronic pulmonary
disease (PD). Current treatment regimens of azithromycin, ethambutol and rifampicin have …

Pericardial tuberculosis (TB) is associated with high therapy failure and high mortality rates.
Antibiotics have to penetrate to site of infection at sufficient non-protein bound …